The Ribosomal Protein S6 Kinase II pipeline drugs market research report outlays comprehensive information on the Ribosomal Protein S6 Kinase II targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ribosomal Protein S6 Kinase II pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology, and Cardiovascular which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), and Congestive Heart Failure (Heart Failure). It also reviews key players involved in Ribosomal Protein S6 Kinase II targeted therapeutics development with respective active and dormant or discontinued products.
The Ribosomal Protein S6 Kinase II pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 2, 1, 1, and 1 respectively.
Ribosomal Protein S6 Kinase II overview
Ribosomal Protein S6 Kinase II (RSK2) is a protein kinase that plays a role in cellular signaling and regulation of gene expression. RSK2 belongs to the family of p90 ribosomal S6 kinases (RSKs). It has a multidomain structure, including an N-terminal kinase domain, a linker region, and C-terminal kinase domains. RSK2 is activated by the mitogen-activated protein kinase (MAPK) pathway. The activation typically involves phosphorylation by extracellular signal-regulated kinases (ERKs) on specific residues. RSK2 phosphorylates a variety of substrates involved in cellular processes such as transcription, translation, and cell survival. Mutations in the RSK2 gene are associated with Coffin-Lowry syndrome, a genetic disorder characterized by intellectual disability and developmental delays. Dysregulation of the RSK pathway has been implicated in certain cancers.
For a complete picture of Ribosomal Protein S6 Kinase II’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.